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Until 2002, coronaviruses (HCoV-NL63, HCoV-229E, HCoV-OC43 and HKU) were first known to cause common cold in humans. However, in 2002 the SARS-CoV emerged, and then in 2013 the MERS-CoV. The SARS-CoV and MERS-CoV caused severe respiratory syndrome and were highly pathogenic for humans, because of their ability to adapt to their host, notably to increase affinity for their receptor, leading to high infectivity in humans ([@CR1], [@CR2]).

In December 2019, a new Coronavirus, first called 2019-nCov and then SARS-CoV-2 for severe acute respiratory syndrome Coronavirus 2, was identified in Wuhan, China ([@CR3]). SARS-CoV-2 spreads very efficiently, causing the current COVID-19 (Coronavirus Disease 2019) pandemic, that by mid-May 2020 has already killed more than 300,000 people all over the world.

The highest morbi-mortality of COVID-19 is observed among older patients ([@CR4]). Patients in intensive care unit (ICU) are older than patients not requiring ICU ([@CR5]). In a study using an observational database from 169 hospitals in Asia, Europe, and North America, an age of more than 65 years-old was associated with a higher risk of in-hospital death: 10.0% mortality rates for people ≥ 65 years-old vs. 4.9% for those \< 65 years-old ([@CR6]). In France, 3.6% of infected individuals needed to be hospitalized, with an average death rate of 0.7% ranging from 0.001% in individuals \< 20 years-old, to 10.1% in those \> 80 years-old ([@CR7]).

Not all older adults appear to be equally vulnerable to SARS-CoV-2 infection ([@CR8]). Frailty is a clinical syndrome in older adults characterized by an increased vulnerability for adverse health outcomes and aging-associated functional declines ([@CR9]). Frail older adults, especially those with comorbidities (eg, hypertension, obesity, diabetes) are at higher risk of death if they get infected than younger adults ([@CR10]). Prevention interventions need to be developed to reduce the impact of COVID-19 in older people. Geroscience is an interdisciplinary field that seeks to understand the links of biological mechanisms of aging with biological mechanisms of disease and body functions (eg, mobility, cognition) to ultimately find potential interventions and promote health in older adults ([@CR11]).

In this perspective paper, we will describe SARS-CoV-2 properties; then we will focus in the relationship between SARS-CoV-2 and aging, discussing the potential roles of comorbidities, inflammaging, immunosenescence, and immune escape. Finally, we will introduce Geroscience as a global approach to treat and prevent the onset and decrease the severity of diseases during aging, notably COVID-19.

SARS-CoV-2 properties {#Sec2}
=====================

Coronaviruses are members of the *Coronaviridae* family. They are divided into *Alphacoronavirus* and *Betacoronavirus* that can only infect mammals, and *Gammacoronavirus* and *Deltacoronavirus* which mostly infect birds ([@CR1]). SARS-CoV-2 is a *Betacoronavirus* (subgroup B Sarbecovirus), enveloped, with a positive single-stranded large RNA that can infect animals and humans. As MERS-CoV and SARS-CoV, it may cause severe diseases and high fatality rate. The envelope spike protein of the SARS-CoV-2 recognizes the human angiotensin-converting enzyme II (ACE2) as an entry receptor, and preferentially infects lung epithelial cells ([@CR12], [@CR13]). The receptor binding domain of the spike protein latches onto the ACE2 receptor, and then the host TMPRSS2 protease cleaves the spike protein to expose fusion peptides able to fuse the viral and cell membranes ([@CR14]).

The cellular tropism of a virus is determined by the susceptibility of host cells to be infected. This is determined, in part, by the presence of the receptor needed for entry: the ACE2 receptor in the case of SARS-CoV-2. ACE2 is expressed in several human tissues, including lungs, small intestine, kidneys, heart, thyroid, adipose tissue, the infection of which by the SARS-CoV-2 can result in diverse symptoms ([@CR15], [@CR16]). Common COVID-19 symptoms are fever, cough, and fatigue. Other symptoms that have also been observed include headache, diarrhea, and anosmia ([@CR17], [@CR18]), demonstrating that SARS-CoV-2 can infect cells in other human organs ([@CR19]). In some cases, however, the infection can be asymptomatic or paucisymptomatic (causing little or no clinical manifestations) ([@CR20]).

Once the SARS-CoV-2 enters a human cell, the virion releases its RNA in the cytoplasm. Translation and replication occur and new virions are then released from the cell through exocytosis ([@CR21]). In COVID-19 pathology, it has been reported that the immune response can be in some cases explosive and deleterious ([@CR22]). Cytokine storm, or Cytokine Release Syndrome (CRS) in peripheral blood is observed in some subjects during the second week of the COVID-19 infection. Approximately 8 days after symptom onset, when it happens in patients, the acute cytokine storm is associated with unfavorable outcomes requiring sometime ICU care and mechanical ventilation. Inflammatory factors elevated during this storm include IL-6 (interleukin 6), IFNγ (interferon γ), TNFα (Tumor necrosis factor α), IL-1β, IL-8, MCP-1 (CCL2 chemokine ligand 2), IP-10 (CXCL10) in peripheral blood as well as antiinflammatory factors such as IL-1RA and IL-10 ([@CR17], [@CR22]--[@CR27]). Elevated IL-6 serum correlates with acute respiratory distress syndrome (ARDS) and multiple-organ failure ([@CR23], [@CR24]). Severe cases of COVID-19 were older, had higher levels of proinflammatory cytokines IL-6, IFN-γ and TNFα, and lower T cell counts (CD8+ and CD4+ T lymphocytes) in the peripheral blood than mild cases ([@CR26], [@CR28], [@CR29]).

Half of the patients hospitalized for COVID-19 had a comorbidity: hypertension, 30%; diabetes, 19%; and coronary heart disease, 8% ([@CR30]). The case-fatality rate was elevated among patients with preexisting comorbidities: cardiovascular diseases, 10.5%; diabetes, 7.3%; chronic respiratory disease, 6.3%; hypertension, 6.0%. and cancer, 5.6% ([@CR4]). Patients infected by SARS-CoV-2 and with diabetes had higher levels of IL-6, IL-8, and TNFα in peripheral blood, and were older than patients without diabetes ([@CR31]). Most of the fatal cases of COVID-19 involved older adults and patients with comorbidities. Cardiovascular diseases, hypertension, cancer, diabetes are also age-related diseases ([@CR32]); and are associated with a chronic inflammation, as aging.

SARS-CoV-2 and aging {#Sec3}
====================

During the current SARS-CoV-2 pandemic, patients in ICU have higher levels of inflammatory factors, and are significantly older and with comorbidities than patients who are not in ICU ([@CR5], [@CR30]). Older age is also associated with a higher peak viral load in the naso-pharynx, suggesting that the virus could replicate at higher rates in older adults, or more probably that their immune system is not efficient enough to limit the infection ([@CR33]--[@CR35]). Differences of ACE2 expression level between young and old adults could contribute to the higher viral loads in older adults, even though this is not established yet in the literature; whereas one study suggests that ACE2 expression in the lung increases with age ([@CR36]), another investigation ([@CR16]) indicates that ACE2 expression levels showed no significant difference between younger and older adults. This discrepancy deserves further studies. When ACE2 expression in the lungs was associated with immune signatures (genes expression of CD8+ T cells, type I IFN response, B cells and NK cells), a positive correlation was observed in the older group and a negative correlation in the younger one ([@CR16]). The ability of the host immune response to combat SARS-CoV-2 infection may partially explain the difference in severity between young and old adults. The induction of proinflammatory cytokines during sepsis (as it may occur in COVID-19 pathology) is not always adequately controlled by anti-inflammatory mechanisms, notably in older patients ([@CR37]). People respond differently to the infection and older patients or those with comorbidities could more frequently have an inappropriate immune response. We can speculate that it is not the SARS-CoV-2 itself, but the inappropriate immune response and the inflammatory process that are responsible for the higher mortality of COVID-19 among older patients ([@CR29], [@CR38]).

In COVID-19 clinical studies, chronological age has been used, whereas all individuals do not age in the same way and the underlying mechanisms of aging may be different. Frailty is a clinical syndrome common in older adults. It has been defined by Fried et al.([@CR9]) as a clinical syndrome in which at least three of the following criteria are present: unintentional weight loss, self-reported exhaustion, weakness, slow walking speed, and low physical activity. Aging and frailty change the clinical presentation of infections, due to alterations in temperature regulation, cognitive decline or malnutrition. Fever may not be detected in older adults and we need to be aware about all the clinical manifestations of COVID-19 for an early identification of frail individuals infected by the SARS-CoV-2 ([@CR29], [@CR39]). There is evidence that inflammaging and immunosenescence have key roles in the pathophysiology of frailty ([@CR40]).

Inflammaging is a low-grade persistent increase in inflammatory mediators ([@CR41]). During aging, chronic antigenic stress (eg, chronic infection, microbiota translocation) leads to chronic low-grade inflammation, as a mechanism of defense; but the regulation by anti-inflammatory molecules is lacking in some older adults and this chronic inflammation become deleterious ([@CR42]). Senescent cells have a Senescence-Associated-Secretory-Phenotype (SASP) and secrete high levels of inflammatory mediators such as IL-6, IL-1β, TNFα and other molecules (IL-18, IL-8, CCL2, CCL11), growth factors and proteases ([@CR41], [@CR43]--[@CR47]). The SASP is a characteristic of senescent cells with arrested cell growth and resistance to apoptosis. It can also be expressed by CD4+ T cells (SA-T) and senescent CD8+ T cells, associating inflammaging and immunosenescence ([@CR48], [@CR49]).

It is well established that the immune response decreases with aging: reduced production of B and T cells in bone marrow and thymus, diminished function of mature lymphocytes in secondary lymphoid tissues, increase in the number of memory T cells, chronic stimulation (with persistent viral infection by Cytomegalovirus and others), impaired function of B cells, and compromised communication between innate and adaptive immunity (Table [1](#Tab1){ref-type="table"}) ([@CR50]--[@CR57]). This series of age-related changes affecting the immune system is called "immunosenescence" ([@CR45]). It affects principally the adaptive immune response. The consequence of immunosenescence is characterized by an increase in vulnerability, and poor resolution of homeostasis following a stress, that may lead to low resilience and frailty. Infections in frail adults often lead to large deterioration and functional dependency which does not return to baseline homeostasis ([@CR40]). The decline immune functions of frail persons may lead to higher SARS-CoV-2 replication and more severe COVID-19. Table 1Characteristics of immunosenescence: decline in immune functions; and immune consequences of SARS-CoV-2 infection in older people**Immune characteristicsMechanismsConsequencesReferences***Immunosenescence*SASP phenotypeInflammaging due to cells with SASPChronic inflammatory state (IL-6)Coppe J-P et al., 2010Chronic stimulationChronic infection such as Cytomegalovirus → cells exhaustion and oligoclonal memory cell expansion; Accumulation of CMV-specific memory CD8+ T cellsMemory inflation; T cells exhaustionKlenerman P et al., 2016Reduction of B and T cells productionStem cell aging with reduced capacity to produce lymphocytes, reduction in the number of B cell and T cell progenitors in bone marrow and thymusVulnerability to infections and cancer; Impaired response to vaccinationGoronzy JJ et al., 2019Reduction of mature lymptocytes functionsAlteration of the composition and quality of the mature lymphocyte pool. Increased number of memory T cellsImpaired B cells functionB cell number reduced in peripheral blood. Decreased numbers of IgM+ memory and switched memory B cellsFrasca D et al., 2009Compromise communication between innate and adaptive immunityActivated naive CD4 T cells have reduced responses to type I IFNLack in the regulation of T cell differentiation and survival. Vulnerability to infectionsShaw AC et al., 2010Low type I and III IFN responseReduced number of plasmacytoid dendritic cells IFN producers; inadequate CD4T cells response to type I IFN stimulation, that impairs IL-2 production and cell survivalAgrawal A et al., 2013 Li et al., 2015*SARS-CoV-2*Low type I and III IFN responseThe host response to SARS-CoV-2 fails to launch robust type I and Type III IFN responses. No recruitment of effector cellsUncontrolled infection by the immune system and clinical severityBlanco-Melo D et al., 2020LymphopeniaSARS-CoV-2 could infect T cells. Apoptosis of lymphocytes induces lymphocytopenia like in MERS-CoV infection?Yang X et al., 2020 Wang X et al., 2020

The immunosenescence is also characterized by a delayed type I interferons (IFN) response ([@CR56]). Type I interferons (IFNs) are polypeptides secreted by infected cells. They induce an antimicrobial state in infected and neighboring cells to limit the spread of the virus. IFNs can also modulate innate immune responses in order to promote antigen presentation, natural killer cell functions and to restrain the production of proinflammatory mediators. Finally, IFNs activate the adaptive immune system (high-affinity antigen-specific T and B cell responses) ([@CR58]). The lack of type I IFN response in frail older adults leads to a low adaptive immune response ([@CR56]). SARS-CoV-2 is a virus sensitive to type I IFN; however, it is also able to limit type I IFN induction([@CR25], [@CR29]). With this function, the virus could escape from the human immune response. Thus, the IFN-I response is limited by the immunosenescence in the host, as well as by the virus itself; explaining why frail patients could be more affected by the COVID-19 (Table [1](#Tab1){ref-type="table"}). Moreover, lymphopenia during COVID-19 infection correlates with clinical severity, and occurs in 80% of critically ill patients ([@CR59]). A recent study from Wang et al., showed that similar to MERS-CoV, the SARS-CoV-2 can infect T cells but failed to replicate in T lymphocytes ([@CR60]). If the SARS-CoV-2 could induces the apoptosis of T cells as the MERS-CoV-2, this could have a significant negative impact on frail older people with already reduced T cell production ([@CR61]).

Taken together, inflammaging and immunosenescence, observed in frail adults, can results in a decrease of the immune system ability to fight new challenges (as SARS-CoV-2 infection). On the other hand, the SARS-CoV-2 may accentuate this immune decline, by its capacity of limiting type I IFN response and maybe infecting T cells. All of this could result in an unstopped SARS-CoV-2 infection and leads to COVID-19 complications in frail older adults.

Geroscience: a global approach to treat and prevent COVID-19 or future pandemic {#Sec4}
===============================================================================

As of May 2020, there are no specific therapies approved for COVID-19 treatment. One strategy is to use drugs that are already approved and known to work at different stages of viral infection and against the immune response. The use of these drugs fast-tracks a treatment plan in a global pandemic situation. Two therapeutic strategies can be distinguished: agents that can target the virus, and agents that protect the host. In the former category, trials are focused on drugs that limit entry or replication (eg, Remdesivir, Lopinavir/Ritonavir, Hydroxychloroquine, IFNα, IFNβ) ([@CR62]). For the latter, the focus is on drugs that can limit the human inflammatory response (eg, corticosteroids, Tocilizumab which is an anti-IL-6R) or boost the innate antiviral immune response (BCG vaccine, type I IFN) ([@CR63]).

The approaches boosting innate antiviral immune response are more interesting for older persons with a weakened immune system, but the risk is to introduce the drugs too late in the infection process. Identifying people at-risk for COVID-19 is necessary to put in place effective and personalized preventive measures. To identify at-risk people, it would be interesting to determine their "immune-age" or "biological age" ([@CR64]) rather than relying only on chronological age. It will ensure a personalized therapeutic care, with benefits against SARS-CoV-2 infection.

In a more global perspective, geroscience should be associated to COVID-19 prevention and treatment ([@CR64], [@CR65]). Geroscience seeks to understand all biological mechanisms (genetic, molecular, and cellular) that make aging a major risk factor of chronic diseases of older adults. The aim is to target the aging process as the single most important risk factor instead of treating just the infection. Treatments that target the molecular pathways of aging could decrease the development and severity of age-related disease, and more globally comorbidities. Among these agents, senolytics can selectively induce death of senescent cells, limiting the accumulation of SASP. Senolytic drugs (eg, quercetin, dasatinib, ruxolitinib) might have a beneficial effect for the prevention or the treatment of SARS-CoV-2 infection by attenuating the cytokine storm and reducing immunosenescence ([@CR67], [@CR68]). mTor inhibitors (eg, rapamycin, RTB101, everolimus) are approved for use in humans and are known to delay age-related diseases in multiple animal models ([@CR69]). A limited number of clinical trials with these drugs are currently being conducted to evaluate their effectiveness against COVID-19 (Table [2](#Tab2){ref-type="table"}) ([@CR70]). Table 2Ongoing clinical trials with anti-aging drugs and COVID-19. (from ClinicalTrials.gov)**Intervention / TreatmentMechanism of actionClinical Trials**SirolimusmTor inhibitor: leads to inhibition of T lymphocyte activation and proliferation; inhibition of antibody productionSirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (SCOPE). Age ≥ 18 years Sirolimus in COVID-19 Phase 1 (SirCO-1). Age: 18--65 years oldNCT04341675 NCT04371640Sirolimus in COVID-19 Phase 1 (SirCO-1). Age: 18--65 years oldNCT04371640Hydroxychloroquine, Azithromycin, SirolimusSenolytic drug: Hydroxychloroquine alkalinizes the pH in lysosomes, which accumulate in large numbers in senescent cellsHydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients (COVID19-HOPE). Age ≥ 18 yearsNCT04374903QuercetinAnti-inflammatory agentEffect of Quercetin on Prophylaxis and Treatment of COVID-19. Age ≥ 18 yearsNCT04377789HydrocortisoneSenolytic drug: SASP inhibitionHydrocortisone for COVID-19 and Severe Hypoxia (COVID STEROID). Age ≥ 18 yearsNCT04348305RuxolitinibSenolytic drug: inhibition of the signalling of cytokines and growth factor receptors that use JAK1 and JAK2 for signallingSafety and Efficacy of Ruxolitinib for COVID-19. 18--89 yearsNCT04348071Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS (RuXoCoil). Age ≥ 18 yearsNCT04359290Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection. 12 years and olderNCT04355793Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation (RuxCoFlam). Age ≥ 18 yearsNCT04338958Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin or TocilizumabCombination of senolytic drugs; antiviral; and immunomodulationRandomized Evaluation of COVID-19 Therapy (RECOVERY). All agesNCT04381936

Comorbidities such as hypertension, coronary heart disease or type 2 diabetes are additional risk factors for COVID-19 pathology and complications ([@CR71]). These comorbidities are also considered to be aging-associated diseases. Current geroscience research aims at determining biological age and could help in the future to determine which older adults are most at risk for complication when infected by SARS-CoV-2. This approach is not specific to COVID-19, and it could be a benefic prevention to protect older adults against future epidemics.

The potential long-term effects of COVID-19 are still unclear. This infection could be a future cause of accelerated aging and frailty. Using geroscience approaches will help to identify this risk.

Conclusions and Perspective {#Sec5}
===========================

In summary, SARS-CoV-2 is an emerging highly transmissible Coronavirus that causes high mortality in the aging population ([@CR6], [@CR7], [@CR72], [@CR73]). The aging population is heterogeneous but most have comorbidities. These comorbidities (eg, hypertension, cardiovascular diseases, obesity, diabetes) are correlated with COVID-19 serious complications ([@CR4]).

The SARS-CoV-2 virus infects human cells by a recognition between the viral spike protein and the human ACE2 receptor ([@CR13]). The increase of the ACE2 receptor expression with age is still debated; but the peak viral load seems correlated with age ([@CR35]).

During aging, immunosenescence and inflammaging are suggested to stand at the origin of frailty and diseases in older individuals ([@CR43]). The inflammaging results of a chronic inflammation, with low-grade production of inflammatory mediators; and the immunosenescence is characterized by a loss in adaptive immune functions that reinforces the need to find treatments that stimulate the innate immune response to protect the organism from infection ([@CR42]). Immunosenescence and inflammaging occurring in some older adults, could be predisposing conditions that sustain the mechanisms by which the SARS-CoV-2 escape the immune surveillance and leads to serious COVID-19 (Figure [1](#Fig1){ref-type="fig"}). Figure 1Circle of aging and SARS-CoV-2 infectionWith age, the immune system declines leading to frailty, comorbidities and high susceptibility to infections. This immune decline can be a predisposing condition sustaining COVID-19 serious complications and explaining high mortality rates in older people with COVID-19. We hypothesize that COVID-19 can be a future cause of accelerated aging and frailty

The effect of aging on the immune system is not uniform among individuals. Now that countries are striking down stay-at-home orders, an ultimate goal would be to identify at-risk older people through their aging profile and develop a personalized approach to limit COVID-19 complications. We propose to use geroscience approaches to identify at-risk people ([@CR74]), develop drugs targeting molecular pathway of aging, and prevent COVID-19 serious complications ([@CR66], [@CR75]).
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